phenomics science (Phenomix), a precision medicine biotechnology company bringing data intelligence to obesity treatment, today announced the launch of a new product. My PhenomTM This test allows patients to test for all three identified phenotypes (emotional hunger, hungry gut, and hungry brain) in one simple test. New tests provide, for the first time, greater insight into the presence of one or more phenotypes, how they affect an individual's obesity, and detailed analysis. My Phenom Test report tailored to the patient.
The obesity phenotype is a combination of genes and other biological data that cause obesity, and was first discovered by the co-founders of Phenomics and physicians at the Mayo Clinic. Andres Acosta, MD and Michael Camilleri, MDDSc. Phenomix's co-founders previously identified that patients can: exhibit multiple phenotypes, has a primary (primary) phenotype and one or more underlying phenotypes.a 2024 survey Linking patients with multiple phenotypes to higher weight and BMI. In particular, obesity treatment tailored to the patient's phenotype is 2x the effect Like any other cure-all.
new My Phenom The examination and report outline the individualized context behind the patient's identified phenotype and cause of obesity. From there, patients can log in. My Phenom A portal for additional resources such as specific meal plans and recipes to complement your phenotype. It also helps healthcare providers develop accurate and effective treatment plans, including lifestyle and dietary interventions, as well as medication and treatment recommendations.
Three phenotypes currently available My Phenom Tests include:
-
emotional hunger – A person who eats in response to emotional triggers and is characterized by high levels of craving, anxiety, and depression. Treatment includes cognitive therapy and medications such as naltrexone/bupropion (Contrave) to reduce emotional eating and increase self-awareness.
-
Hungry Gut – Patients with abnormal satiety experience accelerated gastric emptying. Treatments include the “hungry gut diet,” medications such as semaglutide (GLP-1), certain devices, and bariatric surgery.
-
Hungry Brain – Patients with abnormal satiety require more calories at each meal to reach maximum satiety. Treatments include the “hungry brain diet,” medications such as phentermine topiramate (Qsymia), certain devices, and bariatric surgery.
“The release of our latest test is a testament to our commitment to further understanding the complexity of obesity and finding solutions to it,” said Mark Bagnall, CEO of Phenomics Sciences. said. “This test is more than just a yes or no answer. We provide a deeper understanding of the extent to which these phenotypes affect each patient and provide actionable ways to address them. Backed by powerful machine learning and groundbreaking research, this is just the beginning of unlocking the potential of obesity precision medicine. ”
Phenomix continues to deploy AI tools that analyze genetic and other biological data to understand how phenotype influences an individual's obesity, and to leverage these patient-centered insights. Foster continuous progress.
new My Phenom The test is now available to health care providers across the United States. If you are interested in testing offerings for patients or for more information, please visit: www.phenomixsciences.com.
About Phenomics Science
Phenomix Sciences is a precision obesity biotechnology company with a mission to defeat obesity around the world using proprietary genetic testing, proprietary datasets, and advanced analytics. Mayo Clinic physicians, scientists, and researchers Andres Acosta, MD, and Michael Camilleri, MD, have conducted a 10-year research study focused on understanding the pathophysiology behind variability in response to obesity treatments. The company was founded after rigorous clinical research. Phenomix believes the key to understanding obesity is unprecedented access to clinical and molecular information across all stages and phenotypes of the disease. Phenomix leverages data intelligence to more accurately predict individual patient responses to specific weight loss interventions and reduce variability in patient weight loss outcomes. Learn more about. www.phenomixsciences.com.